Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial

NCT05272826 is registered in ClinicalTrials.gov with Canadian Myeloma Research Group as lead sponsor.

NCT NCT05272826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05272826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial
Lead sponsor
Canadian Myeloma Research Group
Phase
Phase 2
Overall status
Recruiting
Start date
December 12, 2024
Completion date
March 31, 2031
Enrollment
75 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma